|
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst); T-Knife; Zelluna |
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Zelluna |
Other Relationship - iMatch |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
Honoraria - Astellas Oncology |
Patents, Royalties, Other Intellectual Property - Personal IP in radioimmuntherapy |
|
|
Stock and Other Ownership Interests - NEUVOGEN |
Honoraria - Delcath Systems; Transgene |
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN |
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Touchlight Genetics (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems |
Other Relationship - Transgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Achilles Therapeutics |
Stock and Other Ownership Interests - Achilles Therapeutics |
|
|
|
Employment - Achilles Therapeutics |
Stock and Other Ownership Interests - Achilles Therapeutics |
|
|
Employment - Achilles Therapeutics |
Stock and Other Ownership Interests - Achilles Therapeutics |
|
|
Employment - Achilles Therapeutics |
Leadership - Achilles Therapeutics |
Stock and Other Ownership Interests - Achilles Therapeutics |
Honoraria - Autolus; Gilead Sciences; Merck Sharp & Dohme; Takeda |
Consulting or Advisory Role - Autolus; Cytoseek; Gilead Sciences; Takeda |
Speakers' Bureau - Gilead Sciences; Merck Sharp & Dohme |
Patents, Royalties, Other Intellectual Property - Achilles Therapeutics |
Travel, Accommodations, Expenses - Takeda |
|
|
No Relationships to Disclose |